Immatics
immatics.com
Actively hiring
Oncology Therapeutics
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Immatics stock gains 2.22 percent as analysts see upside
Immatics stock trades at USD 7.76 on October 5, 2026, after touching USD 7.40 on October 3. Eight analysts give a Moderate Buy consensus and USD 20.60 average target.
Read more
Report
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death)
Read more
Report
Star Tribune
Your source for Minnesota news today. Read articles, view photos or watch videos about news in Minneapolis, St. Paul, Duluth, St. Cloud, Rochester, and beyond.
Read more
Report
Moderna ties up with Immatics to boost cancer vaccine development
Moderna said the companies would use Immatics' drug discovery platform to develop mRNA-based cancer vaccines, and also study its own cancer vaccine for use in combination with Immatics' cancer therapy...
Read more
Report
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER moleculesCompanies to leverage Imma ...
Read more
Report
Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 42% of the company
Key Insights Significantly high institutional ownership implies Immatics
Read more
Report
BMS joins off the shelf cancer therapy chase with Immatics' T cell-engaging drug
Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient's T cells to go after cancer cells. It's the latest deal in the field of cancer drug developers aiming for off-the-shelf trea
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Immatics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$180k
Typical range
$180k
Open positions
1
1
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $180k | $180k |
Highest paying role
Senior Manager, Learning & Development
$180k
Normalized to USD per year
People
Scientific Advisory
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
7
0 opened / 0 closed in 30 days
ATS activity
Every ~5 hours
10/12/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Operations
25%
QA
13% ▼
Administrative
13% ▲
HR
13% ▲
Management
13% ▼
Field & Service
13% ▲
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
2
Busiest office
Houston
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Houston
United States
HQ
Houston
8 open roles 8 posted in 90 days 13% engineering 200-500 est. staff $180k Avg Salary
hires for Operations, QA, Administrative
Tübingen
Germany
Regional office
Our locations
Financials
Total raised
$1.4M
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2016 | $1.4M | Details |